Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases

[1] Bradford Rice J(2016)Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population J Med Econ 19 649-654

[2] White A(2012)Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population Muscle Nerve 46 496-505

[3] Lopez A(2012)Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population J Rheumatol 39 2303-2309

[4] Galebach P(2013)Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population Lupus 22 268-278

[5] Schepman P(2015)Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States J Rheumatol 42 2383-2391

[6] Popelar B(2013)Impaired quality of life, disability and mental health in Takayasu’s arteritis Rheumatology 52 1898-1904

[7] Furst D(2009)Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions J Rheumatol 36 768-772

[8] Amato A(2005)How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 32 1706-1708

[9] Iorga S(2009)Health-related quality of life for patients with vasculitis and their spouses Arthritis Rheum 61 259-265

[10] Bancroft T(2010)Impaired health-related quality of life in patients treated for Wegener’s granulomatosis J Rheumatol 37 2081-2085

[1] Bradford Rice J(2016)Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population J Med Econ 19 649-654

[2] White A(2012)Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population Muscle Nerve 46 496-505

[3] Lopez A(2012)Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population J Rheumatol 39 2303-2309

[4] Galebach P(2013)Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population Lupus 22 268-278

[5] Schepman P(2015)Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States J Rheumatol 42 2383-2391

[6] Popelar B(2013)Impaired quality of life, disability and mental health in Takayasu’s arteritis Rheumatology 52 1898-1904

[7] Furst D(2009)Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions J Rheumatol 36 768-772

[8] Amato A(2005)How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 32 1706-1708

[9] Iorga S(2009)Health-related quality of life for patients with vasculitis and their spouses Arthritis Rheum 61 259-265

[10] Bancroft T(2010)Impaired health-related quality of life in patients treated for Wegener’s granulomatosis J Rheumatol 37 2081-2085